{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T03:03:31Z","timestamp":1784343811591,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:00:00Z","timestamp":1784332800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:00:00Z","timestamp":1784332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100019084","name":"Kobe University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019084","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To evaluate the real-world use, treatment outcomes, and tolerability of the fixed-dose combination of ripasudil 0.4% and brimonidine 0.1% (RBFC) eye drops in patients with uveitic glaucoma (UG).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study design<\/jats:title>\n                    <jats:p>Single-center retrospective case series.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Medical records of 39 eyes with open-angle UG treated with RBFC were reviewed. The outcome measures included changes in intraocular pressure (IOP) and glaucoma drug score (GDS) at 12 months, the proportion of eyes with an IOP reduction of \u22652 mmHg at 12 months, the relationship between the duration of UG and the change in IOP at 12 months, changes in IOP in eyes switched from ripasudil plus brimonidine, and adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The median IOP significantly decreased from 19 mmHg at baseline to 14 mmHg at 12 months (\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001), while the median GDS showed no significant change, from 3 at baseline to 4 at 12 months (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.562). At 12 months, 64% of eyes achieved an IOP reduction of \u22652 mmHg. A positive correlation was observed between the duration of UG and the change in IOP at 12 months (rho = 0.539,\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.01). In the subgroup analysis restricted to eyes switched from ripasudil plus brimonidine eye drops to RBFC, IOP showed a decreasing trend (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.057). No drug-related adverse events were observed, except for transient conjunctival hyperemia.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This real-world study in patients with UG showed that RBFC achieves effective IOP control while reducing treatment burden, with good tolerability, supporting its continued use in UG management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10384-026-01397-2","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T02:51:56Z","timestamp":1784343116000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world effectiveness and safety of a fixed-dose combination of 0.4% ripasudil and 0.1% brimonidine in the management of uveitic glaucoma"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6458-539X","authenticated-orcid":false,"given":"Sentaro","family":"Kusuhara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Matsumiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotaro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Yamada-Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,18]]},"reference":[{"key":"1397_CR1","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1016\/j.ophtha.2014.07.007","volume":"121","author":"O Tomkins-Netzer","year":"2014","unstructured":"Tomkins-Netzer O, Talat L, Bar A, Lula A, Taylor SR, Joshi L, et al. Long-term clinical outcome and causes of vision loss in patients with uveitis. Ophthalmology. 2014;121:2387\u201392.","journal-title":"Ophthalmology"},{"key":"1397_CR2","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1136\/bjo.74.4.223","volume":"74","author":"WC Panek","year":"1990","unstructured":"Panek WC, Holland GN, Lee DA, Christensen RE. Glaucoma in patients with uveitis. Br J Ophthalmol. 1990;74:223\u20137.","journal-title":"Br J Ophthalmol"},{"key":"1397_CR3","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/00061198-200404000-00003","volume":"13","author":"HM Herbert","year":"2004","unstructured":"Herbert HM, Viswanathan A, Jackson H, Lightman SL. Risk factors for elevated intraocular pressure in uveitis. J Glaucoma. 2004;13:96\u20139.","journal-title":"J Glaucoma"},{"key":"1397_CR4","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1080\/09273940902913035","volume":"17","author":"C Heinz","year":"2009","unstructured":"Heinz C, Koch JM, Zurek-Imhoff B, Heiligenhaus A. Prevalence of uveitic secondary glaucoma and success of nonsurgical treatment in adults and children in a tertiary referral center. Ocul Immunol Inflamm. 2009;17:243\u20138.","journal-title":"Ocul Immunol Inflamm"},{"key":"1397_CR5","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1136\/bjophthalmol-2013-304416","volume":"98","author":"T Kanda","year":"2014","unstructured":"Kanda T, Shibata M, Taguchi M, Ishikawa S, Harimoto K, Takeuchi M. Prevalence and aetiology of ocular hypertension in acute and chronic uveitis. Br J Ophthalmol. 2014;98:932\u20136.","journal-title":"Br J Ophthalmol"},{"key":"1397_CR6","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12348-025-00514-5","volume":"15","author":"S Kusuhara","year":"2025","unstructured":"Kusuhara S, Sonoda KH, Kaburaki T, Fujita T, Katayama S, Makishima M, et al. Real-world treatment patterns for patients with non-infectious uveitis in Japan: a descriptive study using a large-scale claims database (J-CAT study). J Ophthalmic Inflamm Infect. 2025;15:56.","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"1397_CR7","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ajo.2019.06.004","volume":"207","author":"X Liu","year":"2019","unstructured":"Liu X, Kelly SR, Montesano G, Bryan SR, Barry RJ, Keane PA, et al. Evaluating the impact of uveitis on visual field progression using large-scale real-world data. Am J Ophthalmol. 2019;207:144\u201350.","journal-title":"Am J Ophthalmol"},{"key":"1397_CR8","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1136\/bjophthalmol-2021-318809","volume":"106","author":"T Ma","year":"2022","unstructured":"Ma T, Sims JL, Bennett S, Chew S, Niederer RL. High rate of conversion from ocular hypertension to glaucoma in subjects with uveitis. Br J Ophthalmol. 2022;106:1520\u20133.","journal-title":"Br J Ophthalmol"},{"key":"1397_CR9","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.2147\/OPTH.S216907","volume":"14","author":"S Kusuhara","year":"2020","unstructured":"Kusuhara S, Nakamura M. Ripasudil hydrochloride hydrate in the treatment of glaucoma: safety, efficacy, and patient selection. Clin Ophthalmol. 2020;14:1229\u201336.","journal-title":"Clin Ophthalmol"},{"key":"1397_CR10","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s10384-018-0566-9","volume":"62","author":"M Honjo","year":"2018","unstructured":"Honjo M, Tanihara H. Impact of the clinical use of ROCK inhibitor on the pathogenesis and treatment of glaucoma. Jpn J Ophthalmol. 2018;62:109\u201326.","journal-title":"Jpn J Ophthalmol"},{"key":"1397_CR11","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s00417-018-3933-9","volume":"256","author":"S Kusuhara","year":"2018","unstructured":"Kusuhara S, Katsuyama A, Matsumiya W, Nakamura M. Efficacy and safety of ripasudil, a Rho-associated kinase inhibitor, in eyes with uveitic glaucoma. Graefes Arch Clin Exp Ophthalmol. 2018;256:809\u201314.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1397_CR12","doi-asserted-by":"publisher","first-page":"10308","DOI":"10.1038\/s41598-020-66928-4","volume":"10","author":"A Futakuchi","year":"2020","unstructured":"Futakuchi A, Morimoto T, Ikeda Y, Tanihara H, Inoue T, collaborators R-Ssg. Intraocular pressure-lowering effects of ripasudil in uveitic glaucoma, exfoliation glaucoma, and steroid-induced glaucoma patients: ROCK-S, a multicentre historical cohort study. Sci Rep. 2020;10:10308.","journal-title":"Sci Rep"},{"key":"1397_CR13","doi-asserted-by":"publisher","first-page":"904","DOI":"10.18240\/ijo.2023.06.11","volume":"16","author":"R Yanai","year":"2023","unstructured":"Yanai R, Uchi SH, Kobayashi M, Nagai T, Teranishi S, Wakuta M, et al. Efficacy of ripasudil in reducing intraocular pressure and medication score for ocular hypertension with inflammation and corticosteroid. Int J Ophthalmol. 2023;16:904\u20138.","journal-title":"Int J Ophthalmol"},{"key":"1397_CR14","doi-asserted-by":"publisher","first-page":"3559","DOI":"10.1007\/s12325-023-02534-w","volume":"40","author":"H Tanihara","year":"2023","unstructured":"Tanihara H, Yamamoto T, Aihara M, Koizumi N, Minami H, Kojima S, et al. Crossover randomized study of pharmacologic effects of ripasudil-brimonidine fixed-dose combination versus ripasudil or brimonidine. Adv Ther. 2023;40:3559\u201373.","journal-title":"Adv Ther"},{"key":"1397_CR15","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1007\/s00417-024-06388-y","volume":"262","author":"H Tanihara","year":"2024","unstructured":"Tanihara H, Yamamoto T, Aihara M, Koizumi N, Fukushima A, Kawakita K, et al. Long-term intraocular pressure-lowering efficacy and safety of ripasudil-brimonidine fixed-dose combination for glaucoma and ocular hypertension: a multicentre, open-label, phase 3 study. Graefes Arch Clin Exp Ophthalmol. 2024;262:2579\u201391.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1397_CR16","doi-asserted-by":"publisher","first-page":"423","DOI":"10.2147\/OPTH.S446962","volume":"18","author":"K Inoue","year":"2024","unstructured":"Inoue K, Shiokawa M, Kunimatsu-Sanuki S, Tomita G, Ishida K. Switching to brimonidine\/ripasudil fixed combination from brimonidine + ripasudil. Clin Ophthalmol. 2024;18:423\u201330.","journal-title":"Clin Ophthalmol"},{"key":"1397_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13144158","volume":"13","author":"H Onoe","year":"2024","unstructured":"Onoe H, Hirooka K, Baba T, Nagayama M, Hirota A, Suzuki K, et al. The efficacy and safety associated with switching from concomitant brimonidine and ripasudil, or brimonidine or ripasudil monotherapy to a fixed combination of brimonidine and ripasudil in glaucoma patients. J Clin Med. 2024;13:4158.","journal-title":"J Clin Med"},{"key":"1397_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-026-01361-0","author":"K Miyao","year":"2026","unstructured":"Miyao K, Imazeki M, Oyama T, Nakai S, Kanda T, Takeuchi M. Efficacy of ripasudil-brimonidine fixed-dose combination in secondary glaucoma associated with uveitis: a retrospective study. Jpn J Ophthalmol. 2026. https:\/\/doi.org\/10.1007\/s10384-026-01361-0.","journal-title":"Jpn J Ophthalmol"},{"key":"1397_CR19","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.survophthal.2019.12.003","volume":"65","author":"N Kesav","year":"2020","unstructured":"Kesav N, Palestine AG, Kahook MY, Pantcheva MB. Current management of uveitis-associated ocular hypertension and glaucoma. Surv Ophthalmol. 2020;65:397\u2013407.","journal-title":"Surv Ophthalmol"},{"key":"1397_CR20","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1001\/archopht.118.9.1251","volume":"118","author":"DH Johnson","year":"2000","unstructured":"Johnson DH, Matsumoto Y. Schlemm\u2019s canal becomes smaller after successful filtration surgery. Arch Ophthalmol. 2000;118:1251\u20136.","journal-title":"Arch Ophthalmol"},{"key":"1397_CR21","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10384-022-00970-9","volume":"67","author":"Y Kiuchi","year":"2023","unstructured":"Kiuchi Y, Inoue T, Shoji N, Nakamura M, Tanito M, glaucoma guideline preparation committee JGS. The Japan Glaucoma Society guidelines for glaucoma 5th edition. Jpn J Ophthalmol. 2023;67:189\u2013254.","journal-title":"Jpn J Ophthalmol."},{"key":"1397_CR22","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.ophtha.2015.03.026","volume":"122","author":"PA Newman-Casey","year":"2015","unstructured":"Newman-Casey PA, Robin AL, Blachley T, Farris K, Heisler M, Resnicow K, et al. The most common barriers to glaucoma medication adherence: a cross-sectional survey. Ophthalmology. 2015;122:1308\u201316.","journal-title":"Ophthalmology"},{"key":"1397_CR23","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.ajo.2010.09.026","volume":"151","author":"T Krupin","year":"2011","unstructured":"Krupin T, Liebmann JM, Greenfield DS, Ritch R, Gardiner S, Low-Pressure Glaucoma Study G. A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study. Am J Ophthalmol. 2011;151:671\u201381.","journal-title":"Am J Ophthalmol"},{"key":"1397_CR24","doi-asserted-by":"publisher","first-page":"15709","DOI":"10.1038\/s41598-020-72748-3","volume":"10","author":"E Nishijima","year":"2020","unstructured":"Nishijima E, Namekata K, Kimura A, Guo X, Harada C, Noro T, et al. Topical ripasudil stimulates neuroprotection and axon regeneration in adult mice following optic nerve injury. Sci Rep. 2020;10:15709.","journal-title":"Sci Rep"},{"key":"1397_CR25","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.jphs.2024.02.011","volume":"154","author":"K Namekata","year":"2024","unstructured":"Namekata K, Noro T, Nishijima E, Sotozono A, Guo X, Harada C, et al. Drug combination of topical ripasudil and brimonidine enhances neuroprotection in a mouse model of optic nerve injury. J Pharmacol Sci. 2024;154:326\u201333.","journal-title":"J Pharmacol Sci"},{"key":"1397_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2024-001981","volume":"10","author":"K Harimoto","year":"2025","unstructured":"Harimoto K, Nishio Y, Someya H, Sato T, Ito M, Takeuchi M. Anti-inflammatory actions of ripasudil ameliorate experimental autoimmune uveoretinitis in the acute phase. BMJ Open Ophthalmol. 2025;10:e001981.","journal-title":"BMJ Open Ophthalmol"},{"key":"1397_CR27","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1007\/s00417-025-07111-1","volume":"264","author":"B Aguilar-Barrera","year":"2026","unstructured":"Aguilar-Barrera B, Mejia-Salgado G, Cardona-Lopez J, Reyes-Troncoso A, Acosta-Alzamora SD, Escobar-Sanchez DS, et al. Efficacy, effectiveness, and safety of rho-kinase inhibitors in uveitic glaucoma and ocular hypertension secondary to uveitis: a systematic review and meta-analysis. Graefes Arch Clin Exp Ophthalmol. 2026;264:1527\u201340.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1397_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-020-01762-w","volume":"20","author":"S Hopf","year":"2020","unstructured":"Hopf S, Mercieca K, Pfeiffer N, Prokosch-Willing V. Brimonidine-associated uveitis - a descriptive case series. BMC Ophthalmol. 2020;20:489.","journal-title":"BMC Ophthalmol"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-026-01397-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10384-026-01397-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-026-01397-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T02:51:58Z","timestamp":1784343118000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10384-026-01397-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,18]]},"references-count":28,"alternative-id":["1397"],"URL":"https:\/\/doi.org\/10.1007\/s10384-026-01397-2","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,18]]},"assertion":[{"value":"28 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S. Kusuhara, None; W. Matsumiya, None; S. Mori, None; M. Sakamoto, None; Y. Yamada-Nakanishi, None; M. Nakamura, None.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}